AIN457
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout AIN457
AIN457 is a phase 3 stage product being developed by Novartis for Uveitis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01327664. Target conditions include Uveitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04711902 | Phase 3 | Completed |
| NCT01327664 | Phase 3 | Withdrawn |
| NCT01009281 | Phase 2 | Terminated |
Competing Products
20 competing products in Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| triamcinolone acetonide (Triesence®) | Clearside Biomedical | Phase 1/2 | 33 |
| 4 mg CLS-TA Suprachoriodal Injection | Clearside Biomedical | Phase 3 | 69 |
| Baricitinib + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Ixekizumab Prefilled Syringe | Eli Lilly | Approved | 85 |
| adalimumab | AbbVie | Phase 3 | 77 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Approved | 85 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 52 |
| Myfortic | Novartis | Pre-clinical | 23 |
| AIN457 + AIN457 + Placebo AIN457 | Novartis | Phase 3 | 77 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 2 | 52 |
| AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AEB071 | Novartis | Phase 2 | 52 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| Myfortic + Decortin | Novartis | Phase 3 | 77 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 52 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |